Original Title: Daratumumab en mieloma múltiple en recaída o refractario

Authors' recommendations: CONCLUSIONS Moderate-quality evidence suggests that treatment with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone in adult patients with relapsed or refractory multiple myeloma improves progression-free survival and might improve overall survival. Although daratumumab monotherapy has been approved by the regulatory agencies for the treatment of patients with multiple myeloma after failing to three lines of previous treatments or with a proteasome inhibitor and an immunomodulator, very low quality methodological evidence does not allow determining if it would be an alternative in these cases. The clinical practice guidelines consulted suggest it is indicated as an option for these indications as combination therapy, especially in case of first relapse. Most coverage policies consulted, from Europe and United States public and private sponsors cover it. As regards Latin America, the public sponsors consulted do not provide or mention its coverage.

Project Status: Completed

Year Published: 2018

URL for published report: https://www.iecs.org.ar/home-ets/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Argentina

Organisation Name: Institute for Clinical Effectiveness and Health Policy

Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA

Contact Name: info@iecs.org.ar

Contact Email: info@iecs.org.ar

Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)